Outlook Therapeutics (OTLK) to Release Quarterly Earnings on Wednesday

Outlook Therapeutics (NASDAQ:OTLK) will likely be issuing its quarterly earnings data before the market opens on Wednesday, February 12th. Analysts expect the company to announce earnings of ($0.85) per share for the quarter.

Outlook Therapeutics (NASDAQ:OTLK) last released its quarterly earnings data on Friday, December 27th. The company reported ($0.77) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.06. On average, analysts expect Outlook Therapeutics to post $-2 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Outlook Therapeutics Stock Performance

Shares of NASDAQ OTLK opened at $1.83 on Wednesday. Outlook Therapeutics has a 1 year low of $0.87 and a 1 year high of $12.85. The firm has a market cap of $58.36 million, a price-to-earnings ratio of -0.20 and a beta of 0.58. The stock’s 50-day simple moving average is $1.87 and its 200-day simple moving average is $4.81.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on OTLK. Chardan Capital reaffirmed a “neutral” rating on shares of Outlook Therapeutics in a research report on Monday, December 2nd. Guggenheim reiterated a “buy” rating and issued a $12.00 price target on shares of Outlook Therapeutics in a research note on Friday, January 17th. BTIG Research decreased their price target on Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating for the company in a research note on Friday, November 29th. Finally, HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Outlook Therapeutics in a research note on Friday, January 17th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, Outlook Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $27.40.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.